Triple Threat-Triple Benefit: The Rise of GLP1-GCG-FGF21 Tritagonists in Tomorrow’s Metabolic Medicine . Diabzen, [S. l.], v. 3, n. 3, p. 43–48, 2025. Disponível em: https://www.thediabzen.com/index.php/d/article/view/19. Acesso em: 14 apr. 2026.